Federal
Register Notices > Importers
>
Fisher Clinical Services Inc.
FR Doc E7-22486 [Federal Register: November 16, 2007 (Volume 72, Number
221)] [Notices] [Page 64678-64679] From the Federal Register Online via GPO
Access [wais.access.gpo.gov] [DOCID:fr16no07-142]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a registration
under this Section to a bulk manufacturer of a controlled substance in
schedule I or II and prior to issuing a registration under 21
U.S.C. 952(a)(2) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title
21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on
June 22, 2007, Fisher Clinical Services Inc., 7554 Schantz Road, Allentown,
Pennsylvania 18106, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Noroxymorphone (9668),
a basic class of controlled substance listed in schedule II. The company plans
to import the listed substance for analytical research and clinical trials.
Any bulk manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic class of controlled substance may file
comments or objections to the issuance of the proposed registration and may,
at the same time, file a written request for a hearing on such application
pursuant to 21
CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC
20537, or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than
December 17, 2007.
This procedure is to be conducted simultaneously with, and independent of,
the procedures described in 21
CFR Sec. 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice
published in the Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
[[Page 64679]]
Control, Drug Enforcement Administration, that the requirements for such
registration pursuant to 21
U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 6, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-22486 Filed 11-15-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|